ACADIA Pharmaceuticals Inc. 0A4W.L Stock
ACADIA Pharmaceuticals Inc. Price Chart
ACADIA Pharmaceuticals Inc. 0A4W.L Financial and Trading Overview
ACADIA Pharmaceuticals Inc. stock price | 15.34 USD |
Previous Close | 24.99 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 26 USD |
Volume | 390 USD |
Avg. Volume | 461 USD |
Market Cap | N/A |
Beta (5Y Monthly) | 0.525352 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.334 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0A4W.L Valuation Measures
Enterprise Value | 3.72B USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 10.5878525 |
Enterprise Value/Revenue | 7.154 |
Enterprise Value/EBITDA | -22.94 |
Trading Information
ACADIA Pharmaceuticals Inc. Stock Price History
Beta (5Y Monthly) | 0.525352 |
52-Week Change | 23.81% |
S&P500 52-Week Change | 20.43% |
52 Week High | 26 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 21.95 USD |
200-Day Moving Average | 17.92 USD |
0A4W.L Share Statistics
Avg. Volume (3 month) | 461 USD |
Avg. Daily Volume (10-Days) | 112 USD |
Shares Outstanding | N/A |
Float | 110.72M |
Short Ratio | N/A |
% Held by Insiders | 0.22% |
% Held by Institutions | 97.70% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -28.053% |
Operating Margin (ttm) | -31.55% |
Gross Margin | 29.07% |
EBITDA Margin | -31.18% |
Management Effectiveness
Return on Assets (ttm) | -16.037% |
Return on Equity (ttm) | -35.63% |
Income Statement
Revenue (ttm) | 520.23M USD |
Revenue Per Share (ttm) | 3.21 USD |
Quarterly Revenue Growth (yoy) | 2.60% |
Gross Profit (ttm) | 145.49M USD |
EBITDA | -162228000 USD |
Net Income Avi to Common (ttm) | -145940000 USD |
Diluted EPS (ttm) | -1.334 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 402.87M USD |
Total Cash Per Share (mrq) | 2.48 USD |
Total Debt (mrq) | 60.61M USD |
Total Debt/Equity (mrq) | 16.2 USD |
Current Ratio (mrq) | 2.242 |
Book Value Per Share (mrq) | 2.305 |
Cash Flow Statement
Operating Cash Flow (ttm) | -55639000 USD |
Levered Free Cash Flow (ttm) | 68.01M USD |
Profile of ACADIA Pharmaceuticals Inc.
Country | United Kingdom |
State | CA |
City | San Diego |
Address | 12830 El Camino Real |
ZIP | 92130 |
Phone | 858 558 2871 |
Website | https://acadia.com |
Industry | |
Sector(s) | |
Full Time Employees | 540 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Q&A For ACADIA Pharmaceuticals Inc. Stock
What is a current 0A4W.L stock price?
ACADIA Pharmaceuticals Inc. 0A4W.L stock price today per share is 15.34 USD.
How to purchase ACADIA Pharmaceuticals Inc. stock?
You can buy 0A4W.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ACADIA Pharmaceuticals Inc.?
The stock symbol or ticker of ACADIA Pharmaceuticals Inc. is 0A4W.L.
How many shares does ACADIA Pharmaceuticals Inc. have in circulation?
The max supply of ACADIA Pharmaceuticals Inc. shares is 0.
What is ACADIA Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
ACADIA Pharmaceuticals Inc. PE Ratio is now.
What was ACADIA Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
ACADIA Pharmaceuticals Inc. EPS is -1.334 USD over the trailing 12 months.